Frontlight ResearchEarly access
TerminatedPhase 1
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
Key facts
- Who runs it
- Yale University
- Where
- New Haven, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 7 people enrolled
- Started
- 21 Feb 2023
- Ended
- 31 Jan 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- adnectin 18F-BMS-986192 Head and Neck Cancer
- adnectin 18F-BMS-986192 Brain Metastases
- Record updated
- 15 February 2024
- Why it stopped
- PI changed institutions
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Patients with resectable squamous cell carcinoma of the oropharynx (HPV positive and HPV negative)
- Resectability will be confirmed by a surgical co-investigator
- If available, HPV-association determined by institutional p16 testing (CINtec antibody demonstrating strong and diffuse nuclear and cytoplasmic staining is at least 70% of cells)
- Absolute neutrophil count (ANC) > 1500/microliter, absolute lymphocyte count (ALC) >1000/microliter, hemoglobin > 9 g/dl, platelets > 100,000/microliter
- aspartate aminotransferase (AST) and alanine transaminase (ALT) < 5 x upper limit of normal. Bilirubin < 1.5 x upper limit of normal
- Albumin > 0 g/dl
- Creatinine < 5 x upper limit of normal
- Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to treatment
- Patients with brain metastases
- Tumor size equal or greater than 1 cm
- Resectability or need for laser interstitial thermal therapy (LITT) will be confirmed by a surgical co-investigator
- Absolute neutrophil count (ANC) > 1500/microliter, absolute lymphocyte count (ALC) >1000/microliter, hemoglobin > 9 g/dl, platelets > 100,000/microliter
- AST and ALT < 5 x upper limit of normal. Bilirubin < 1.5 x upper limit of normal
- Albumin > 0 g/dl
- Creatinine < 5 x upper limit of normal
- Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to treatment
Who cannot take part
- Medical contraindication to surgery
- Concomitant invasive malignancy, or malignancy within 2 years except for hormonally responsive breast or prostate cancer, resected non-melanoma skin cancer, resected uterine cervical carcinoma
- Prior systemic therapy, radiation or gross resection for the tumor under study
- Receipt of other systemic therapy including investigational agents, radiation or gross resection for treatment of the tumor under study
- Medical contraindication to brain surgery
- Full dose anticoagulation
- Inability to give informed consent
- Women may not be pregnant or breast-feeding
- Full dose anticoagulation
- Inability to give informed consent
- Women may not be pregnant or breast-feeding
Where in United States
- Yale University PET CenterNew Haven, United States
About the trial
What the trial wants to find out
This study aims to determine the feasibility of non-invasive quantitative PD-L1 measurement using [a novel PD-L1 positron emission tomography (PET) tracer and perform immunohistochemistry based measurement of PD-L1 levels within resected lesions in head and neck cancer and brain metastases.
The 2 groups in the trial
- Head and neck cancerTreatment being tested
Participants with head and neck squamous cell carcinoma who plan to undergo tumor resection and lymph node resection.
Treatment: adnectin 18F-BMS-986192 Head and Neck Cancer
- Brain MetastasesTreatment being tested
Participants with metastases to the brain from melanoma, lung cancer, breast cancer.
Treatment: adnectin 18F-BMS-986192 Brain Metastases
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
- Record updated
- 15 February 2024